Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05655312 · ClinicalTrials.gov registry record · Phase 1

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

A Phase 1 study of Metastatic Melanoma and Melanoma Stage IV, sponsored by Perspective Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
300
Enrollment target
13
Study locations

NCT05655312 is a Phase 1 study of Metastatic Melanoma and Melanoma Stage IV that is actively recruiting participants, run by Perspective Therapeutics. The registered enrollment target is 300 participants, above the 80-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (275% higher). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05655312, a Phase 1 study of Metastatic Melanoma and Melanoma Stage IV, is actively recruiting participants, sponsored by Perspective Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
300 participants
Enrollment target
13
Study locations

Study Summary

In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic melanoma.

Conditions Studied

Metastatic Melanoma Melanoma Stage IV Melanoma Stage III Recurrent Melanoma (Skin)

Interventions

  • DRUG Nivolumab
  • DRUG [203Pb]VMT01
  • DRUG [212Pb]VMT01

Study Locations (13)

Florida

  • Mayo Clinic - Jacksonville
  • University of Miami - Miami
  • Sarasota Memorial Hospital - Sarasota

Missouri

  • Saint Louis University Hospital - St Louis
  • Washington University of St. Louis - St Louis

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia
  • UPMC Hillman Cancer Center - Pittsburgh

California

  • University of California Irvine - Orange

Iowa

  • University of Iowa - Iowa City

Kentucky

  • University of Kentucky - Lexington

Minnesota

  • Mayo Clinic Rochester - Rochester

Nebraska

  • Nebraska Cancer Specialists - Omaha

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-06-01
Est. Completion 2029-12-31
Phase Phase 1

Sponsor

Perspective Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05655312

The ClinicalTrials.gov registry entry for NCT05655312 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 80-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (275% higher). The listed sponsor is Perspective Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT05655312 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Florida, Missouri, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05655312 about?

NCT05655312 is a clinical study titled "MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma". In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic me...

What is the current status of trial NCT05655312?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2023-06-01. Estimated completion is 2029-12-31.

What conditions does trial NCT05655312 study?

This clinical trial studies the following conditions: Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III, Recurrent Melanoma (Skin).

What interventions are being tested in trial NCT05655312?

The interventions under investigation include: Nivolumab (DRUG), [203Pb]VMT01 (DRUG), [212Pb]VMT01 (DRUG).

Who is sponsoring clinical trial NCT05655312?

This trial is sponsored by Perspective Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05655312 being conducted?

This trial has 13 study locations across California, Florida, Iowa, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Melanoma

All registered trials for this condition

Melanoma Stage IV

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.